The Science of Pressurised Repair: HBOT, the Hyperoxic-Hypoxic Paradox, and Why the Chamber Matters

In 1960, a Dutch surgeon named Ite Boerema published a paper with one of the best titles in medical history: "Life Without Blood."

Boerema took anaesthetised pigs, placed them in a hyperbaric chamber at 3 atmospheres of pressure, and then drained out almost all of their red blood cells, replacing the volume with plasma substitute. Haematocrit fell to a level that should have been rapidly fatal. The animals survived, because at that pressure enough oxygen had dissolved directly into their plasma to keep every tissue supplied without any haemoglobin doing the work at all.

That experiment is the whole of hyperbaric medicine in one image. Under sufficient pressure, oxygen stops behaving like a gas your blood cells carry and starts behaving like something dissolved in your blood the way sugar dissolves in tea.

Which is a useful thing to remember the next time someone offers you a zip-up inflatable bag and calls it the same therapy.

From the diving bell to the geroscience lab

Hyperbaric Oxygen Therapy, or HBOT, began as an emergency intervention: decompression sickness in divers, carbon monoxide poisoning, gas gangrene, crush injuries and compromised skin grafts, and wounds that refuse to close because the tissue simply cannot get enough oxygen to build new blood vessels.

That work is mature, evidence-graded and internationally recognised. The Undersea and Hyperbaric Medical Society maintains a defined list of approved indications, and for those conditions HBOT is not alternative medicine. It is standard care.

What is newer, and considerably more speculative, is the interest from geroscience, the study of the biology of ageing. Over the last decade researchers, most prominently the group at the Sagol Center for Hyperbaric Medicine in Israel, have asked a different question: if repeated high-pressure oxygen can push a stubborn wound to grow new capillaries, what else in the body might respond to the same signal?

The early answers are genuinely interesting. They are also, we will argue, widely overstated on the internet. Let us do both parts properly.

The biology: the hyperoxic-hypoxic paradox

Here is the counterintuitive bit, and it is the thing most articles get wrong. The regenerative signal does not come from the oxygen itself. It comes from the change in oxygen.

This is called the hyperoxic-hypoxic paradox, and it works in four steps.

First, saturation. Inside a clinical chamber, you breathe 100% medical-grade oxygen at 2.0 atmospheres absolute, written as ATA, or higher. Henry's Law tells us that the amount of gas dissolving into a liquid rises in proportion to the pressure above it, so oxygen is driven directly into your blood plasma, bypassing haemoglobin entirely. Tissue oxygen tension rises to many times its normal baseline.

Second, the air break. At intervals, you are switched back to ordinary air for a few minutes. This is not a rest period for your comfort. It is a deliberate part of the protocol.

Third, the trick. Your cells do not measure absolute oxygen. They measure change. When levels drop sharply from extreme hyperoxia back towards normal, the cell's molecular sensors read it as a hypoxic emergency, even though tissue oxygen is still comfortably above baseline. The alarm goes off without the cell ever actually being starved.

Fourth, the cascade. That false alarm activates HIF-1 alpha, or Hypoxia-Inducible Factor 1-alpha, a master transcription factor that switches on repair programmes: angiogenesis, meaning the growth of new microvasculature, and the mobilisation of stem and progenitor cells out of bone marrow into circulation. Alongside this, the controlled oxidative load appears to drive mitohormesis, the process by which a manageable dose of metabolic stress prompts cells to clear damaged mitochondria and build new ones.

If that last mechanism sounds familiar, it should. It is the same adaptive logic that makes exercise work: apply a controlled stressor, let the body over-correct, keep the upgrade. HBOT is not a shortcut around that principle. It is another way of invoking it.

What the longevity research actually showed

The study everyone cites is Hachmo and colleagues, published in the journal Aging in 2020.

What they did: 35 healthy, independently living adults aged 64 and over received 60 HBOT sessions across 90 days, five days a week, 90 minutes each at 2.0 ATA. Blood was sampled at baseline, at session 30, at session 60 and once more afterwards.

What they found: telomere length in several immune cell populations increased by roughly 20% to 38% depending on cell type, and the proportion of senescent cells fell by roughly 11% to 37%.

That is a striking result, and it deserves to be read carefully rather than shouted. The caveats matter.

There was no control group. This was a single-arm prospective trial, and without a comparison arm you cannot cleanly separate the intervention from time, seasonality, regression to the mean, or the general effect of 60 supervised visits to a medical centre. The sample was small: thirty-five people is a signal, not a settlement. The variability was enormous, with several reported changes carrying standard deviations larger than the effect itself, which means individual responses ranged widely, some participants moving a great deal and some barely moving. It measured circulating immune cells, not brain, heart, liver or muscle, so whether the same occurs in solid tissue remains an open question. And telomere length is a marker, not an outcome: nobody has yet shown that lengthening telomeres in peripheral blood cells translates into longer healthspan in humans. It is a plausible proxy that we are still validating.

None of this makes the finding uninteresting. It makes it early. There is a meaningful difference between a promising mechanism with published human data and a therapy clinically proven to reverse ageing, and any clinic that blurs those two is selling you something.

Our position: HBOT for its established indications is well-evidenced medicine. HBOT in the context of healthy ageing is a serious and fast-moving research field that we follow closely, offer transparently, and describe honestly.

Clinical chambers versus recreational bags

This is where the consumer market gets genuinely misleading, so it is worth being blunt. A mild soft chamber and a clinical hard-shell system are not two versions of the same thing.

A soft chamber is an inflatable canvas or polyurethane bag, reaching 1.3 to 1.5 ATA, roughly 10 to 15 feet of seawater, with the occupant breathing ambient air at 21% or a concentrator feed of variable purity. The increase in plasma oxygen is marginal, supervision is often absent, and its reasonable uses are things like mild altitude symptoms and general relaxation.

A clinical hard-shell system is a steel or reinforced acrylic vessel reaching 2.0 to 3.0 ATA, roughly 33 to 66 feet of seawater, delivering 100% medical-grade oxygen through a fitted mask or hood. The rise in plasma oxygen is large and dose-dependent, a trained team screens and monitors throughout, and this is the range the published research actually uses.

The awkward detail nobody advertises

In clinical trials, pressures in the region of 1.2 to 1.3 ATA are frequently used as the sham control. Which is to say: the mild pressure sold to consumers as the therapy is, in much of the research literature, the placebo.

We should be fair here, because this is genuinely debated. Some researchers argue low-pressure air is not perfectly inert and may exert mild effects of its own, which is precisely why it makes an imperfect sham. But the direction of the argument tells you what you need to know. If a pressure is chosen because investigators expect it to do very little, it is a strange foundation for an industry.

Soft-shell chambers are not dangerous when used sensibly. They are simply not the intervention in the studies people quote when selling them.

Oxygen under pressure is a drug

This is the part of the article that matters most, and the part we would ask you to actually read.

HBOT is not a spa treatment with a medical aesthetic. Oxygen delivered under pressure is a pharmacologically active agent with a dose-response curve, a therapeutic window and a toxic ceiling. Three things require a trained team.

The first is central nervous system oxygen toxicity. At raised partial pressures, oxygen becomes neurotoxic. Get the dose, session length or air-break schedule wrong and you can precipitate a seizure, a phenomenon described by Paul Bert in the nineteenth century and taken extremely seriously ever since. The scheduled air breaks in a clinical protocol exist specifically to keep cumulative exposure below that threshold.

The second is barotrauma. Gas trapped in body cavities expands and contracts with pressure, per Boyle's Law. Without careful compression rates and proper ear-equalisation coaching, the middle ear and sinuses are at real risk. Pulmonary barotrauma, including arterial gas embolism, is rarer but far more serious, which is why breath-holding during ascent is forbidden and why certain lung conditions must be excluded beforehand.

The third is contraindication screening. Untreated pneumothorax is an absolute contraindication. Certain chemotherapy agents, significant obstructive airways disease, some cardiac conditions, uncontrolled fever, recent ear surgery and pregnancy all require physician assessment before anyone steps into a chamber.

The compression itself is the easy part. The clinical judgement around it is the actual service.

Where this fits into a longevity programme

We are a longevity practice, not a chamber rental company, so here is how we think it should be sequenced.

First, screen. Before any hyperbaric protocol you need medical clearance: cardiac and respiratory assessment, ear examination, medication review, contraindication check. This is not a formality to be waved through.

Second, establish a baseline. If you intend to run a 60-session protocol over three months, you should know what you looked like before you started. At Hayat Longevity that means a comprehensive biomarker panel, inflammatory and metabolic markers, wearable and sleep data, and a structured functional assessment. If you are considering a hyperbaric protocol, that longevity baseline is the honest place to begin, because it is the only way to know afterwards whether it did anything for you specifically.

Third, build the foundation. HBOT does not replace the things that reliably work. Zone 2 aerobic training, resistance work, sleep, protein intake and glycaemic control are the base of the pyramid. Hyperbaric protocols sit near the top, and a pyramid with no base is just an expensive point.

Fourth, measure again. Repeat the panel afterwards. Because the published response is so variable between individuals, group averages tell you very little about you. Your own before-and-after data tells you rather a lot.

As for where to do it in Penang, our hyperbaric centre in George Town operates a hard-shell clinical chamber under medical supervision, with proper screening and monitored protocols. Everything begins with a consultation, because the first question is never which protocol to run. It is whether you should be in a chamber at all. If you are already in Penang for medical care, the logistics are unusually straightforward.

Boerema's pigs survived without blood because physics made oxygen do something it does not normally do. Sixty-five years later we are still working out how far that principle extends, and the honest answer is that we know a great deal about wounds and rather less about ageing. What we can promise is that we will keep telling you which is which.